Paper Title
Choosing Wisely: A Comparative Analysis of Generic and Branded Anti-Hypertensive Drugs Telmisartan And Metoprolol Succinate
Article Identifiers
Registration ID: IJNRD_222839
Published ID: IJNRD2405820
: Click Here to Get
About Hard Copy and Transparent Peer Review Report
Authors
Keywords
Generic drug’s , Branded drug’s , Safety , Efficacy , Affordability , Cost of therapy for generic drug’s , health policy , Scope , Objectives and Definition , Methodology , etc.
Abstract
High blood pressure, or hypertension, is a prevalent heart ailment that affects a large proportion of the world's population. High blood pressure medication is commonly used to treat the condition. Antihypertensive drugs are prescribed in medicine with both brand and generic names. The goal of this study is to compare generic and branded versions of two commonly prescribed antihypertensive drugs, telmisartan and metoprolol succinate, based on quality. This study considered a number of evaluation factors, including weight variation, weight uniformity, hardness, brittleness, disintegration, and dissolution. The use of brand-name or generic drugs has recently caused much debate on a global scale. Furthermore, the governments of a number of countries actively encourage the use of generic pharmaceuticals instead of name-brand medications. A generic drug has therapeutic efficacy similar to its brand-name counterpart and includes the same active ingredient or substances. Generic drugs are much less expensive than name-brand medications since they do not have to go through the extensive and costly preclinical or clinical trials that brand-name medications undertake, which significantly raises the cost of those prescriptions. This analysis provides an overview of the comparative effectiveness of metoprolol succinate and telmisartan generics versus name-brand drugs. The objective also attempts to draw attention to the discrepancies in prices between the two categories, as well as the laws and controls surrounding both pharmaceuticals.
Downloads
How To Cite (APA)
Saniya Dastagir Pathan , Shahin Mehboob Pathan, Dipti Vilas Sable, Swarup Manohar Harne, & Dr. Wakale V.S. (May 2024). Choosing Wisely: A Comparative Analysis of Generic and Branded Anti-Hypertensive Drugs Telmisartan And Metoprolol Succinate. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 9(5), I177-I189. https://ijnrd.org/papers/IJNRD2405820.pdf
Issue
Volume 9 Issue 5, May-2024
Pages : I177-I189
Other Publication Details
Paper Reg. ID: IJNRD_222839
Published Paper Id: IJNRD2405820
Research Area: Pharmacy
Author Type: Indian Author
Country: Pune, Maharashtra , India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2405820.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2405820
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
UGC CARE JOURNAL PUBLICATION | ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Copyright & License
© 2025 — Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License. and The Open Definition.
You are free to share, adapt, and redistribute the material, provided proper credit is given to the original author. 🛡️ Disclaimer: The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-Reviewed, Refereed, and UGC CARE Journal Publication with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost, and Transparent Peer Review Journal Publication that adheres to the UGC CARE 2025 Peer-Reviewed Journal Policy and aligns with Scopus Journal Publication standards to ensure the highest level of research quality and credibility.
IJNRD offers comprehensive Journal Publication Services including indexing in all major databases and metadata repositories, Digital Object Identifier (Crossref DOI) assignment for each published article with additional fees, citation generation tools, and full Open Access visibility to enhance global research reach and citation impact.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse academic and professional fields. The journal promotes global knowledge exchange among researchers, developers, academicians, engineers, and practitioners, serving as a trusted platform for innovative, peer-reviewed journal publication and scientific collaboration.
Indexing Coverage: Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many other recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
You can now publish your research in IJNRD. IJNRD is a Transparent Peer-Reviewed Open Access Journal Publication (Refereed Journal), aligning with New UGC and UGC CARE recommendations.
For more details, refer to the official notice: UGC Public Notice
Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: December 2025
Current Issue: Volume 10 | Issue 12 | December 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 31-Dec-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
Approval, Licenses and Indexing: More Details
